Resolution of abnormal ALT, steatosis and fibrosis (as estimated using non-invasive liver markers cut-off) from baseline to 1 year in continuous care intervention (CCI) and usual care (UC)
| Variables | CCI | UC | |||||
| Baseline | 1 year | P value* | Baseline | 1 year | P value* | Between-groups p values† | |
| Full cohort | n=262 | n=87 | |||||
| Abnormal ALT, n (%)‡ | 153 (58) | 60 (23) | 8.1×10–11 | 38 (44) | 35 (40) | 0.664 | 0.006 |
| NAFLD-LFS | |||||||
| >−0.640, n (%) | 250 (95) | 197 (75) | 7.9×10–10 | 80 (92) | 79 (91) | 0.678 | 0.002 |
| NAFLD fibrosis score | |||||||
| <−1.455, n (%) | 46 (18) | 87 (33) | 3.9×10–7 | 23 (26) | 22 (25) | 1.0 | 0.139 |
| Abnormal ALT at baseline | n=153 | n=38 | |||||
| NAFLD-LFS | |||||||
| >−0.640, n (%) | 151 (99) | 117 (76) | 1.8×10–7 | 35 (92) | 37 (97) | 0.625 | 0.007 |
| NAFLD fibrosis score | |||||||
| <−1.455, n (%) | 30 (20) | 56 (37) | 4.1×10–5 | 11 (29) | 11 (29) | 1.0 | 0.266 |
NAFLD-LFS cut-off >−0.640 for detecting liver fat >5.56% (sensitivity: 86% and specificity: 71%).
NAFLD fibrosis score <−1.455 corresponds with low probability of advanced fibrosis (NPV ≈ 92%) and >0.675 indicates high probability of advanced fibrosis (PPV ≈ 85%).
*McNemar’s test.
†χ2 tests were used when appropriated.
‡Abnormal ALT refers to >19 U/L for women and 30 U/L for men.
ALT, alanine aminotransferase; LFS, liver fat score; NAFLD, non-alcoholic fatty liver disease; NPV, negative predictive value; PPV, positive predictive value.